Efficacy of Date Palm Leaf Extract (Phoenix dactylifera) in Patients with COVID-19 Hospitalized in Ganjavian Hospital in Dezful

Efficacy of Palm Leaf Extract (Phoenix dactylifera) in Patients with COVID-19 Patients Admitted to Ganjavian Hospital in Dezful with Mild to Moderate Stages: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201015049036N1

Enrollment

100

Registered

2020-11-27

Start date

2020-09-12

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirous (COVID19). Corona virus infection, unspecified

Interventions

Intervention 1: Intervention group: treatment- medicine: Phoenix medicine (contains hydro alcoholic solution, Phoenix leaf extract, Vitamin C and Strawberry flavoring) 5 times/day, each time 5 ml. Int

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients >12 years of age (male/female) with mild to moderate disease, which can be determined by clinical criteria (dry cough, fever and dyspnea) and paraclinical indices PO2, PCR, CT Scan, CRP, CBC Signing the form of consent by persons >18 years of age or the guardians of the under-aged patients

Exclusion criteria

Exclusion criteria: Dissatisfaction of patients or the patients' guardians Any allergic reactions from the use of the palm extract Critically ill patients or the cases where the physician in chief may not recommend this intervention for hospitalized patients

Design outcomes

Primary

Measure	Time frame
Lung infection. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: CT Scan.;Virus diagnosis. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: PCR.;Fever. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Thermometer.;PaO2: oxygen pressure in arterial blood. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Record the degree of oxygen pressure.;CRP: reactive protein in blood for detect the inflammation. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test.;ESR: erythrocyte sedimentation rate used to monitor inflammatory diseases. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test.;WBC: white blood cell. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test.	—

Measure

Time frame

Lung infection. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: CT Scan.;Virus diagnosis. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: PCR.;Fever. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Thermometer.;PaO2: oxygen pressure in arterial blood. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Record the degree of oxygen pressure.;CRP: reactive protein in blood for detect the inflammation. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test.;ESR: erythrocyte sedimentation rate used to monitor inflammatory diseases. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test.;WBC: white blood cell. Timepoint: At the beginning of entering the plan, at the end of the first week of treatment and at the end of the second week of treatment. Method of measurement: Comparison with normal standard range in blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Dorchin

Dezfoul University of Medical Sciences

dr.dorchin@gmail.com+98 61 4255 6011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026